Camurus AB
STO:CAMX
Camurus AB
Cost of Revenue
Camurus AB
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Camurus AB
STO:CAMX
|
Cost of Revenue
-kr129.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Cost of Revenue
-kr104.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Orexo AB
STO:ORX
|
Cost of Revenue
-kr72.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
E
|
Enzymatica AB (publ)
STO:ENZY
|
Cost of Revenue
-kr14.9m
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-12%
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Cost of Revenue
-kr1.6B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-116%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Cost of Revenue
-kr19.7m
|
CAGR 3-Years
42%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
Camurus AB
Glance View
Camurus AB is a Swedish pharmaceutical company that stands out in the industry with its innovative approach to treating chronic and rare diseases. Rooted in its proprietary FluidCrystal® injection depot technology, Camurus integrates this platform into the development of long-acting medications that aim to improve patient compliance and outcomes. This lipid-based system allows for the extended release of active substances, providing sustained therapeutic effects from just a single dose. Founded in 1991, the company has strategically focused its efforts on areas often underserved by traditional pharmaceutical giants, such as addiction, pain management, and endocrine disorders. By concentrating on these specific therapeutic areas, Camurus not only addresses significant health challenges but also carves out a niche with limited competition, potentially leading to substantial revenue streams. The company generates its income predominantly through product sales and strategic partnerships. One of its flagship products is Buvidal®, a long-acting medication for the treatment of opioid dependence, which has made significant inroads across Europe and Australia. The sustained revenue from Buvidal® highlights the company's adeptness at capitalizing on its technology to create tangible healthcare solutions. Additionally, Camurus engages in licensing agreements and collaborations with international pharmaceutical firms, expanding its market reach and leveraging its technology across a broader canvas. By investing heavily in research and development, Camurus ensures its pipeline continues to be robust, with new products consistently in various stages of clinical trials, thereby securing its financial performance and position in the pharmaceutical industry.
See Also
What is Camurus AB's Cost of Revenue?
Cost of Revenue
-129.5m
SEK
Based on the financial report for Dec 31, 2024, Camurus AB's Cost of Revenue amounts to -129.5m SEK.
What is Camurus AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-41%
Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for Camurus AB have been -15% over the past three years , -41% over the past five years .
You don't have any saved screeners yet